Tag Archives: regulatory pathway for biosimilars

Biosimilars Ahead, Proceed with Caution

Richard Dolinar

By Richard M. Dolinar, M.D., Chairman, Alliance for Safe Biologic Medicines In today’s budget-constrained world, the goal for health care is not only to save lives but also to save money. On Friday, May 11, the Food and Drug Administration (FDA) will hold a one-day public hearing on important medicines, known as biosimilars, that are under FDA consideration to come to the United States (U.S.) and offer the opportunity to help achieve the second prong Read More >

Health  |  1 Comment  |  Email This Post
Tags: , , , , , , , , ,

BIO, Here We Come!

Angie Drakulich from PharmaTech Talk writes: Next week is the annual Biotechnology Industry Organization (BIO) Convention in Washington, DC. Many of our editorial team members will be there and we hope to see you. With a regulatory pathway for biosimilars underway in the United States, renewed conversations about regenerative medicine, and a booming biotech sector, the convention should be quite dynamic. Angie is part of our BIO Official Blog Program. Keep an eye on her Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , ,